serine and arginine rich splicing factor 4Genealiases: SFRS4 · SRP75
Q-omics provides the consensus-scored SRSF4 profile across patient tissues and cancer cell-line models. SRSF4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SRSF4 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SRSF4 protein abundance shows 27,580 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where SRSF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRSF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRSF4 survival associations across molecular data types. SRSF4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRSF4 RNA expression–survival associations across cancer types. High SRSF4 expression shows unfavorable associations in ACC, KIRC, LGG, KICH, LIHC and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SRSF4 RNA expression.
This table summarizes SRSF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SRSF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRSF4 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, BLCA and STAD. The HNSC box plot shows higher SRSF4 RNA expression in tumor versus normal tissue (log2 FC = +0.720, t-test p < 0.001).
This table shows molecular features associated with SRSF4 in patient tissues and cancer cell lines. In patient samples, SRSF4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRSF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
